#138-Lauren Rogen & Richard Isaacson MD: Alzheimer's disease prevention—patient & doctor perspective

Richard Isaacson frames exercise as the number one intervention unconditionally — above all supplements, dietary changes, and pharmaceutical options. He distinguishes two categories: physical activity (accumulated movement, better than nothing) and physical exercise (structured, progressive, with cardiovascular and strength components). For e4 carriers, the intensity dimension is critical. Lauren's uncle — APOE 4/4 like her mother but an obsessive cyclist with leg muscles described as extraordinary — developed symptoms roughly 15 years later, suggesting exercise was the dominant modifier of disease timeline.

Isaacson has been recommending omega-3s for Lauren for several years before the formal proof came out in 2020 — he calls this 'we hedged our bets and then it was proven.' He checks red blood cell DHA/EPA index, not plasma levels, because RBC levels reflect 90-day integration of intake and better predict brain DHA.

Isaacson cites studies by Littlejohn and Cedric Annweiler as sources for the vitamin D–cognition relationship. He notes that Lauren's initial level of 17–19 was 'definitely not sufficient' and that they have since fully corrected this as one of the earlier biomarker wins in her prevention program.

Isaacson references this as one of Lauren's early targeted modifications — her homocysteine was part of the blood panel that informed the initial protocol. The synergistic interaction between B vitamins and omega-3s in slowing brain atrophy was established in an Oxford study; Isaacson uses it to justify measuring both rather than treating blindly.

Lauren carries both APOE4 and a TNF-alpha co-modifier gene that Isaacson discovered when trying to explain why she would have higher risk than her APOE4 alone would predict. TNF-alpha (tumor necrosis factor-alpha) drives neuroinflammation; theracumin may modulate this pathway. Isaacson does not disclose any supplement company relationships.

Isaacson explicitly says he does not care about cellulite on the thighs — it is the visceral fat that drives cognitive risk. He speculates that Lauren's mother, while not obviously obese, may have accumulated visceral fat over her 40s and 50s ('skinny fat') that contributed to her disease course.

Attia introduces Mg-L-threonate to Isaacson as a newer option. Isaacson is particularly intrigued by the sleep benefit as a co-mechanism — improving sleep quality in perimenopausal women may itself reduce amyloid accumulation via glymphatic clearance.

Isaacson maps biomarker trajectories to predicted cognitive domains: high homocysteine leads to expect processing speed/attention deficits; early Alzheimer's pathology means watch memory and naming tasks; vascular risk factors correlate with executive function. Lauren had a catastrophically bad session the day a documentary was released due to extreme emotional stress and poor lifestyle compliance. The next two sessions showed dramatic improvement after she re-engaged the protocol with Attia's help.

Isaacson also screens for the full polygenic picture: TNF-alpha co-modifier, TOMM40 chain length (the adjacent TOMM40 gene may modulate e4 penetrance such that not all APOE4s are created equal), FTO and PCSK9 vascular genes, CLU, PICALM, BIN1, and longevity genes (FOXO, Klotho). The practical entry point is APOE because it is the most clinically validated and actionable.

The mechanism Isaacson describes: precipitous estrogen withdrawal leads to bioenergetic shift in the brain, which drives hot flashes, night sweats, sleep disruption, processing-speed deficits (what he refuses to call 'brain fog'), and in genetically susceptible women, acceleration of amyloid and tau pathology. He is deliberately careful: perimenopause does not mean you will get Alzheimer's. But in a 4/4 woman undergoing surgical menopause — removing ovaries along with the uterus and inducing immediate hormone withdrawal — 'that could do it.' He now consults with an OB-GYN every other week to refine the hormone-type and delivery-route questions.

Practical implication discussed: rather than immediately fitting hearing aids in a 35-year-old with mild low-grade loss, the near-term action is noise protection to preserve remaining function and then formal audiological screening at appropriate ages. Attia notes there is no downside to protecting hearing. Isaacson calls it a systemic failure that most physicians are not routinely checking hearing during preventive visits.

Isaacson describes three stages: pre-clinical (pathology in the brain, no symptoms — an estimated 46 million Americans), MCI due to Alzheimer's (more than 1.5 SD below norm, still self-caring, 12–16% per year conversion rate to dementia), and dementia (worse symptoms plus functional impairment). He emphasizes that symptoms at stage two or three mean pathology has been accumulating for 20–30 years — the only phase where prevention is fully available is the pre-clinical phase.

Isaacson is conducting one of the only studies doing comprehensive brain imaging on men and women aged 40–65 to tease apart the muscle-mass vs. fat-distribution vs. hormonal contributions. He notes widowhood is an astronomically important risk factor for cognitive decline — women outlive men and are disproportionately widowed, adding social isolation to the hormonal burden.

Key numeric targets: omega-3 index at least 12–14 in red blood cells (target 14 or above), vitamin D at least 50 ng/mL (APOE 4/4 may need 50–70), homocysteine controlled with B-complex (B12, B6, folate), ApoB treated aggressively. Lauren's vitamin D was 17–19 on first visit; her cognitive scores shifted from 0.87 SD below mean to greater than 90th percentile over ~5 years. Isaacson also checks trans fat levels in blood as an imperfect but useful signal.

Lauren's odor score improved over time on the protocol — Isaacson notes this may partly reflect practice effects (learning to distinguish coffee from gasoline smell on the test cards) but considers it a meaningful signal alongside her other improvements. He flags COVID-19-related anosmia as a complication for future use of the test, noting his own 5–6 week smell loss followed by phantom smells during recovery.